Renal Diseases Pharmaceutical and Healthcare Analysis Information
The renal diseases therapy area encompasses a range of diseases of the kidney, such as chronic kidney disease (CKD), acute kidney injury, diabetic nephropathy and focal segmental glomerulosclerosis. Renal diseases are becoming increasingly common due to the increased prevalence of hypertension and diabetes, two major causes of CKD. For most forms of renal diseases, early detection and management may slow down or prevent progression to renal failure and associated complications. However, many renal diseases are typically asymptomatic until they have progressed to end-stage renal disease (ESRD), which requires renal replacement therapies such as hemodialysis and renal transplantation, and is associated with substantial morbidity and mortality.
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2478897-frontier-pharma-renal-diseases-high-degree-of-innovation-and-diversity-with
The marketed treatments of renal diseases typically focus on controlling the risk factors and complications of renal failure. Treatments include anti-hypertensive agents, hormones, antibiotics, and immunosuppressants. However, these treatments are often not wholly effective, as patients are still at risk of dying prematurely from cardiovascular disease or progressing to ESRD. Few new renal disease therapies have reached the market in the past decade, and with the rising prevalence, there is a high need for innovation and investment in the renal diseases therapy area.
The report assesses first-in-class innovation in the renal diseases pipeline, highlighting key trends and emerging treatment classes. There are 100 first-in-class products in development in this therapy area, which account for 39% of products in the overall pipeline for which there is a disclosed molecular target, and act upon 77 unique individual molecular targets. First-in-class innovation is concentrated heavily at the early drug development stages.
The first-in-class programs identified show considerable diversity, and the relatively high degree of innovation in the renal diseases therapy area makes for a promising development pipeline. It is clear that recent activity in this area has increased, partly owing to the growing recognition of the unmet medical need. Further investment in innovation would benefit the therapy area greatly, and likely prove a worthwhile investment, particularly for highly prevalent diseases such as CKD and diabetic nephropathy, for which there are a lack of effective pharmacotherapeutic options.
- With 365 products in active development, the pipeline is modestly sized. Does current pipeline innovation hold the potential to affect the future renal diseases market?
- There are 100 first-in-class products in the renal diseases pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
- The majority of first-in-class products were in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
- A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?
Reasons to buy
- Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the renal diseases market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the renal diseases pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating renal diseases to overcome the level of unmet need.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: renal failure, glomerulonephritides, and renal scarring. Promising targets have been reviewed in greater detail.
- Identify commercial opportunities in the renal diseases deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals
Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Unmet Need and Limited Treatment Options Despite Rising Prevalence 5
2.2 Increasing Number of Pipeline Biologics 5
2.3 Significant Degree of First-in-Class Innovation 5
2.4 Low Deal Volume but Large Proportion of High-Value Deals 6
3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 8
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation 9
3.6 GBI Research Report Guidance 10
4 Clinical and Commercial Landscape 11
4.1 Disease Overview 11
4.2 Symptoms 12
4.2.1 Acute Kidney Injury 12
4.2.2 Chronic Kidney Disease 12
4.3 Diagnosis 12
4.3.1 Acute Kidney Injury 12
4.3.2 Chronic Kidney Disease 13
4.4 Etiology and Pathophysiology 13
4.4.1 Renal Anatomy and Physiology 14
4.4.2 Pathophysiological Processes of Renal Diseases 14
ACCESS REPORT @ https://www.wiseguyreports.com/reports/2478897-frontier-pharma-renal-diseases-high-degree-of-innovation-and-diversity-with
Get in touch:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
WISE GUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renal Diseases Pharmaceutical and Healthcare Analysis Information here
News-ID: 809226 • Views: 248
More Releases from WISE GUY RESEARCH CONSULTANTS PVT LTD
Global Electronic Smart Mask Market 2020 -2026
Electronic Smart Mask Market 2020 -2026 New Study Reports “Electronic Smart Mask Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026” has been Added on WiseGuyReports. Introduction/Report Summary: This report provides in depth study of “Electronic Smart Mask Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Electronic Smart Mask Market report also provides an in-depth survey of key players in the market which is based on the various objectives
Global Variable Universal Life Insurance Market 2020-2026
Variable Universal Life Insurance Market 2020-2026 New Study Reports “Variable Universal Life Insurance Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026” has been Added on WiseGuyReports. Introduction/Report Summary: This report provides in depth study of “Variable Universal Life Insurance Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Variable Universal Life Insurance Market report also provides an in-depth survey of key players in the market which is based on
Training Outsourcing 2020 Global Market Key Players – TrainingFolks, AllenComm …
Training Outsourcing Market 2020-2026 New Study Reports “Training Outsourcing Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026” has been Added on WiseGuyReports. Introduction/Report Summary: This report provides in depth study of “Training Outsourcing Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Training Outsourcing Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as
3D Reconstruction Technology Market 2020 Global Analysis By Key Players – Pix4 …
3D Reconstruction Technology Market 2020-2026 New Study Reports “3D Reconstruction Technology Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026” has been Added on WiseGuyReports. Introduction/Report Summary: This report provides in depth study of “3D Reconstruction Technology Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The 3D Reconstruction Technology Market report also provides an in-depth survey of key players in the market which is based on the various objectives of
More Releases for Innovation
Global Innovation Management Industry
Global Innovation Management Industry Latest Report on Innovation Management Market Global Analysis & 2023 Forecast Research Study Global Innovation Management market is expected to grow from $288.25 million in 2016 to reach $1,963.17 million by 2023 with a CAGR of 31.5%. Rising requirement for crowd sourcing innovations from different organizations, shifting work cultures and growing scope for companies due to the development of new and innovative products are some drivers which are
Innovation at its Best
Berlin, 17.10.2013– Model Engineering Solutions (MES) introduces latest products Quality Checker and Model Examiner DRIVE to the public at VDI Electronic Systems for Motor Vehicles. With these innovations MES once again demonstrates technological leadership in quality assurance of model-based software development. MES reveals both products at VDI Electronic Systems for Motor Vehicles in Baden-Baden (Germany), at booth No. 68 on the first floor of the exhibition hall. Shine a Searchlight
20 Years of Innovation
2012 – A year of celebration for Innovative Technology! 2012 will see the start of a year of celebration for Oldham based bank note validator manufacturer Innovative Technology Ltd (ITL) as they celebrate 20 years of Innovation! Founded in 1992 by David Bellis MBE, Innovative Technology Ltd (ITL) was the first company to manufacture low cost multi-currency validators, when it introduced the NV1 Smiley® to the market - making banknote validators affordable
Innovation for heavy industry
Novel encoder promises an exceptionally long service life As of December 2011 Johannes Hübner GmbH, based in Gießen, Germany, will be introducing a worldwide first to the market in the form of its looper encoder ALS 40 K. Thanks to unique design characteristics this special encoder offers twice to three times the length of service life usual to date. In hot rolling mills loopers have two tasks to fulfil: they measure and
MENTOR: The Innovation Effect
Under the motto “The Innovation Effect” the MENTOR GmbH & Co. Praezisions-Bauteile KG presents innovative developments and customer specific solutions for diverse product fields at this year’s electronica, the world’s leading fair for electronics and electrical engineering. On about 90 m² exhibition space the global group of companies shows its technical developments and design concepts of mechanical, electronic and optoelectronic components for the electronics and automotive industries. The know-how of a
RFID Innovation in Healthcare
RFID Tribe\'s Dallas, Texas Chapter Meets to Discuss RFID Innovation in Healthcare Dallas, Texas (July 6, 2007) - RFID Innovation in Healthcare is the theme for RFID Tribe\'s Dallas, Texas chapter meeting scheduled for July 20, 2007. RFID Tribe chapter meetings bring together RFID technology practitioners in metropolitan areas for networking, presentations and collaboration. Dr. JC Chiao, associate professor at the University of Texas at Arlington, will make a presentation \"RFID